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Defective interfering particle, EHV-1
Gene regulation, EHV-1Defective interfering particles (DIP) of equine herpesvirus 1 (EHV-1) inhibit standard virus replication and
mediate persistent infection. The DIP genome is comprised of only three genes: UL3, UL4, and a hybrid
gene composed of portions of the IR4 (EICP22) and UL5 (EICP27) genes. The hybrid gene is important for
DIP interference, but the function(s) of the UL3 and UL4 genes are unknown. Here, we show that UL4 is an
early gene activated solely by the immediate early protein. The UL4 protein (UL4P) was detected at
4 hours post-infection, was localized throughout the nucleus and cytoplasm, and was not present in
puriﬁed virions. EHV-1 lacking UL4P expression was infectious and displayed cell tropism and pathogenic
properties in the mouse model similar to those of parental and revertant viruses. Reporter assays
demonstrated that the UL4P has a broad inhibitory function, suggesting a potential role in establishing
and/or maintaining DIP-mediated persistent infection.umor Virology, Department of
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.
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Equine herpesvirus 1 (EHV-1), a member of the Alphaherpesvirinae
subfamily, is amajorpathogenof equinesworldwide, resulting in severe
respiratory, neurological, and abortigenic disease (Allen and Bryans,
1986;Mettenleiter et al., 2008;O'Callaghan andOsterrieder, 2008).Viral
replication requires the gene program to be regulated in a coordinated
and temporal fashion, following a progression from immediate early
(IE) to early (E) to late (L) gene expression (Caughman et al., 1985; Gray
et al., 1987). EHV-1 encodes six regulatory proteins that govern the viral
gene program, ﬁve being important in promoter activation and one
serving as a negative regulatory protein. The sole IE protein (IEP) trans-
activates early and some late EHV-1 gene promoters and is capable of
trans-repressing its own promoter (Smith et al., 1992). Early proteins
IR4P and UL5P function synergistically with the IEP to enhance
expression of early and late promoters (Albrecht et al., 2004; Holden
et al., 1995; Kim et al., 1997; Zhao et al., 1995). EICP0P is an early
regulatory protein that independently serves as a potent and promis-cuous trans-activator of EHV-1 genes of all temporal classes (Bowles
et al., 1997). The late ETIF protein is a tegument protein responsible for
activating expression of the sole IE gene (Lewis et al., 1993; Purewal
et al., 1994) and is essential for secondary envelopment and virus egress
(von Einem et al., 2006). The early IR2 protein is a truncated form of the
IE protein (Harty and O'Callaghan, 1991) and serves to down-regulate
the expression from all classes of viral promoters (Kim et al., 2006).
Lastly, the EHV-1 unique IR3 gene encodes a transcript that is antisense
to the IE mRNA (Holden et al., 1992), is not translated to a detectable
protein product (Ahn et al., 2007), and functions to down-regulate
expression of the IE gene (Ahn et al., 2010).
Like many viruses (Huang and Baltimore, 1970), EHV-1 passaged
at high multiplicity will form defective interfering particles (DIP) that
can mediate a state of persistent infection (Campbell et al., 1976;
Dauenhauer et al., 1982; Ebner et al., 2008; Ebner and O'Callaghan,
2006). Present within the DIP genome (~7.5 kbp; Fig. 1B) are the
origin of replication, cis elements for cleavage and packaging, and only
three genes: UL3 and UL4 conserved perfectly from the left terminus
of the standard genome (~155 kbp; Fig. 1A) and a unique hybrid gene
formed by a recombination event that joins portions of the IR4 and
UL5 regulatory genes (Chen et al., 1996, 1999; Ebner and O'Callaghan,
2006). The IR4/UL5 hybrid gene (Hyb) negatively affects expression of
many viral genes during DIP-mediated persistent infection (Chen
et al., 1999). Recent studies demonstrated that the IR4 portion of the
Hyb protein is important for mediating this negative regulation as
well as interfering with standard virus replication (Ebner et al., 2008).
Fig. 1. Genomes of the standard EHV-1 and EHV-1 defective interfering particles.
(A) Organization of the EHV-1 standard (STD) genome and location/orientation of
the regulatory genes and genes conserved within the DIP genome. UL unique long
region; US unique short segment; IR inverted repeat segment. Numbers show size
of viral proteins in amino acid residues. (B) DIP genome comprised of a 7.5 kbp
repeat. CPS cleavage/packaging sequence, ORI origin of DNA replication; Hyb
hybrid gene of IR4/UL5 sequences.
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persistent or lytic infection. In the present study, we identify the
UL4 gene as an early gene and demonstrate that the UL4 proteinFig. 2. Characterizing UL4 as an early gene through metabolic inhibitor studies, norther
with EHV-1 with a UL4 speciﬁc oligonucleotide indicates that UL4 is an early gene. (B) M
(CHX) and phosphonoacetic acid (PAA) were used to treat RK13 cells infected with E
isolated from treated (+) and untreated (−) cells at 4 hpi for CHX and 8 hpi for PAA,
kinase (TK), and UL4 genes. (C and D) Luciferase reporter assays were performed to ex
seeded in 24-well plates were transfected with 1 pmol of the pUL4–Luc reporter plasm
pCMV–UL4, pCMV–ETIF and pSV–IR2; either individually (C) or in combination with th
bars show standard deviation of triplicate assays.(UL4P) has a nuclear and cytoplasmic localization and is not a
component of puriﬁed EHV-1 virions. A possible regulatory function
of the UL4P was examined through transient transfection assays
which revealed that the UL4P inhibited the expression of reporter
genes under the control of EHV-1 promoters of all gene classes as
well as the promoters of heterologous viruses and cell genes tested
to date. In addition, the absence of the UL4P resulted in an increase
in the amount of viral transcripts of all gene classes during
infection. Studies with a mutant EHV-1 lacking UL4 expression
showed that the UL4P was not essential for viral replication in cell
culture or a pathogenic phenotype in the CBA mouse model.Results
The UL4 gene belongs to the early class in the EHV-1 gene program
A previous report described the location of the 5′ and 3′ termini
of the UL4 mRNA in relation to a TATA box and polyadenylation
signal, respectively (Harty et al., 1993). We set out to characterize
UL4 gene transcription and assign the UL4 gene to a temporal class
in the EHV-1 gene program. Northern blot analysis with a
nucleotide probe speciﬁc for the UL4 transcript ﬁrst detected
a ~0.9 kb mRNA at 2 hour post-infection (hpi) which reached
maximal expression levels by 7 hpi (Fig. 2A). These data suggest
that UL4 is an early gene. Additionally, metabolic inhibitor studies
demonstrated that the UL4 gene is not transcribed when protein
synthesis is inhibited by cycloheximide (CHX; Fig. 2B); whereas, IEn blotting, and luciferase assays. (A) Northern blot analysis of RK13 cells infected
etabolic inhibitors were used to conﬁrm that UL4 is an early gene. Cycloheximide
HV-1 to inhibit protein synthesis or viral DNA replication, respectively. RNA was
and northern blot analysis was performed using probes for the IE, early thymidine
amine the activation of the UL4 promoter by EHV-1 regulatory proteins. RK13 cells
id and 0.5 pmol of the effector plasmids pSV–IE, pSV–UL5, pSV–EICP0, pCMV–IR4,
e IEP (D). Luciferase activity was measured at 48–72 hours post-transfection. Error
368 R.A. Charvat et al. / Virology 412 (2011) 366–377mRNA, as expected, is detected in the presence and absence of
CHX. Furthermore, the UL4 transcript like that of the early
thymidine kinase (TK) transcript was synthesized when viral
DNA replication was inhibited by phosphonoacetic acid (PAA).
These data conﬁrm that UL4 belongs to the early gene class, a
ﬁnding further supported by the absence of a TAATGARAT motif
within the UL4 promoter. This motif is present within the promoters
of immediate early genes of other alphaherpesviruses (Lewis et al.,
1997; Misra et al., 1994; Moriuchi et al., 1995), including the sole IE
gene of EHV-1 (Elliott and O'Hare, 1995; Grundy et al., 1989), and is
the target sequence for binding by the viral α-trans-inducing factor
(Elliott and O'Hare, 1995). Furthermore, in the reporter assays
employing theUL4 promoter region inserted upstream of a luciferase
reporter gene, the EHV-1 α-trans-inducing factor (ETIF) failed to
activate the UL4 promoter, whereas the IEP strongly trans-activated
the UL4 promoter (Fig. 2C), conﬁrming that UL4 is an early gene.
Additional studies concerning the activation of the UL4 promoter by
combinations of plasmids that express EHV-1 regulatory proteins
indicated that the IEP alone trans-activated the UL4 promoter
maximally, and that no synergistic activation occurred when the
IEP was co-expressed with other EHV-1 regulatory proteins (Fig. 2D).
Characterization of the UL4 protein
To begin to characterize the UL4 protein, a rabbit polyclonal anti-
UL4P speciﬁc antibody was generated (Materials and methods). To
verify the speciﬁcity of the anti-UL4P antibody, RK13 cells were
transfected with plasmids that express UL4P, UL4 fused to either the
carboxy- or amino-terminus of the green ﬂuorescent protein (GFP), or
GFP alone or cells were infected with RacL11 EHV-1. Cell lysates were
harvested and subjected to western blot analysis using the OC95 anti-
UL4P antibody and a mouse monoclonal anti-GFP antibody. In the
transfected cells, the anti-GFP antibody detected bands corresponding toFig. 3. UL4 protein synthesis and absence of the UL4 protein in puriﬁed EHV-1 virions. React
western blot analyses of lysates of RK13 cells transfected with various expression constructs
48 hours post-transfection and at 24 hours post-infection were subjected to western blot an
OC95 anti-UL4P antibody. (C) Western blot analyses of lysates of EHV-1 infected RK13 cells
antibodies speciﬁc for the EHV-1 UL31 DNA-binding protein, glycoprotein D, or UL4P.GFP (26 kDa; Fig. 3A lane2), theGFP–UL4 fusion protein (46 kDa; Fig. 3A
lane 7), and the UL4–GFP fusion protein (46 kDa; Fig. 3A lanes 5 and 6).
This anti-GFP antibody also detected GFP (Fig. 3A lane 8) in lysates of
cells infected with the BAC-derived RacL11 virus that expresses the GFP
gene inserted during the generation of the BAC (Rudolph et al., 2002).
The anti-UL4P antibody detected a 23 kDa protein from cells transfected
with UL4 expression plasmids (Fig. 3B lanes 3 and 4) as well as from
infected cell lysates (Fig. 3B lane 8). Additionally, the anti-UL4P
antibody detected theUL4–GFP fusionprotein (Fig. 3B lanes 5and6) and
the GFP–UL4 fusion protein (Fig. 3B lane 7). No bands were detected
with the anti-UL4P antibody inmock transfected cells (Fig. 3B lane 1) or
cells transfected with the GFP expression plasmid (Fig. 3B lane 2). Thus,
the OC95 antibody was highly speciﬁc for the UL4P and demonstrated
very little cross reactivity with cellular proteins.
A time course experiment was completed to examine UL4
protein translation. Western blot analysis of lysates of infected RK13
cells with the puriﬁed rabbit anti-UL4P antibody revealed that the
23 kDa protein seemed to accumulate after 4 hpi (Fig. 3C). To
determine whether the UL4 protein is a component of the EHV-1
virion, puriﬁed virus particles were prepared and subjected to
western blot analyses. Nitrocellulose membranes were reacted with
primary antibodies speciﬁc for the UL4P, glycoprotein D (gD), an
envelope glycoprotein essential for EHV-1 replication (Csellner
et al., 2000; Flowers and O'Callaghan, 1992; Frampton et al.,
2005), and the EHV-1 nonstructural UL31 protein, the major DNA
binding protein (Lewis et al., 1995). As shown in Fig. 3D, the
preparation of virions was free of cellular protein contamination as
demonstrated by the lack of the nonstructural UL31 protein in the
virion preparation, whereas this protein was present in large amounts
in lysates of infected cells. As a positive control, the anti-gD antibody
reacted with viral protein present in both infected cell lysates and
puriﬁed virions. In contrast, the anti-UL4P antibody reacted strongly
only with infected cell lysates and failed to react with proteins in theivity and speciﬁcity of the OC95 anti-UL4 protein polyclonal antiserum were veriﬁed by
and lysates of cells infected with BAC-derived (bd) RacL11 EHV-1. Lysates prepared at
alysis and reacted with either (A) a mouse monoclonal antibody to GFP or (B) puriﬁed
with the puriﬁed anti-UL4P antibody. (D) Western blot analysis of puriﬁed virions with
369R.A. Charvat et al. / Virology 412 (2011) 366–377puriﬁed virion preparation, indicating that the UL4P is not a
component of the EHV-1 virion.
Utilizing themonospeciﬁc anti-UL4P antibody, immunoﬂuorescence
assays were completed to determine the cellular localization of the
UL4 protein in RK13 cells transfected with plasmids expressing
either the UL4 gene or the UL4–GFP fusion gene, or cells infected with
EHV-1. Expression of the UL4 protein (Fig. 4A) or the UL4–GFP
fusion protein (Fig. 4B) in the absence of other viral proteins
resulted in a broad distribution of the UL4P within both the
cytoplasm and nucleus of these cells. A similar ﬂuorescent staining
pattern was observed in cells infected with EHV-1 (Fig. 4C),
suggesting that the 23 kDa UL4 protein localizes within both the
nucleus and cytoplasm during infection. To verify the localization
of the UL4 protein in both cellular compartments, RK13 cells were
infected with EHV-1, and cell lysates were separated into
cytoplasmic and nuclear fractions as described in the Materials
and Methods. Western blot analysis of the proteins isolated from
these cellular fractions conﬁrmed that the UL4 protein was located
within both the cytoplasm and nucleus (data not shown).
UL4P is an inhibitor of gene expression and antagonizes IEP
trans-activation of EHV-1 promoters
Although known to be conserved perfectly within the genome of
defective interfering particles (Baumann et al., 1984, 1986; Ebner
et al., 2008; Ebner and O'Callaghan, 2006), no function has been
reported for UL4. Herpes simplex virus 1 (HSV-1) UL55, the UL4P
homolog, was demonstrated to inhibit transient gene expression
when co-transfected into cells along with plasmids expressing the
immediate early gene α27 as well as alpha genes α0 and α4 (Block
et al., 1991). Additionally, Yamada et al. (1998) characterized the
UL55 protein of HSV-2 as a potential accessory protein in virion
assembly and maturation and found it to co-localize with capsid
protein ICP35 at the periphery of infected cell nuclei. To determine
whether UL4P possesses any regulatory activity, luciferase reporter
assays were performed. The reporter plasmid expressed the ﬁreﬂy
luciferase gene under the control of various EHV-1 promoters,
including the immediate early (IE), early promoters EICP0, thymidine
kinase (TK), and IR2, and late promoters ETIF and glycoprotein K (gK).Fig. 4. Localization of the UL4 protein in transfected and EHV-1 infected cells by immunoﬂuo
(A) pCMV–UL4 or the (B) pUL4–GFP expression plasmid, or (C) were infected with RacL11
12 hours post-infection and permeabilized with 0.2% Triton X100 in PBS. Panels A and C: pur
anti-rabbit IgGwas the secondary antibody. Panel B shows ﬂuorescence due to GFP expressio
panel). Arrows in the upper panels indicate the nuclei of the cells of interest stained in theRabbit kidney cells were transfected with the various reporter
plasmids along with the effector plasmids pSV–IE and/or pCMV–UL4,
and luciferase activity was measured at 48–72 hours post-transfection.
For the IE promoter, luciferase activity was inhibited by 77% in the
presence of the UL4 protein (Fig. 5A). In a separate reporter assay
employing the chloramphenicol acetyltransferase (CAT) gene under
the control of the EHV-1 IE promoter, UL4 protein expression
inhibited CAT activity by 87% (data not shown). UL4P expression
decreased luciferase activity for the early EHV-1 TK and IR2
promoters 95% and 85%, respectively (Figs. 5C and D). In addition,
luciferase activity driven by EHV-1 late promoters was negatively
affected by the UL4P, such that in the case of the ETIF and gK
promoters the inhibition reached levels of 78% and 98%, respectively
(Figs. 5E and F). Conversely, when cells were transfected with the IE
effector plasmid, luciferase activity was greatly increased for the early
promoters and theETIFpromoter;whereas, the late gKpromoter and the
IE promoter were inhibited by expression of the IE protein, conﬁrming
our previous reports (Caughman et al., 1985; Harty and O'Callaghan,
1991; Kim et al., 1999; Smith et al., 1992, 1994). When the UL4 and IE
expression plasmids were co-transfected into cells, the ability of the IEP
to trans-activate the early EICP0, TK, IR2, and late ETIF promoters was
diminished (Figs. 5B to E). IEP trans-activation of these four
promoters was inhibited by 45% to 70%. The IEP has been shown to
inhibit its own promoter (Harty and O'Callaghan, 1991; Smith et al.,
1994), and the coexpression of the UL4 and IE proteins further
abrogated the luciferase activity driven by the IE promoter (Fig. 5A).
These data suggest that the UL4 protein plays an inhibitory role in
governing the expression of EHV-1 genes.
Given that the UL4P appeared to function across all gene classes,
we next wanted to establish if the negative effect on reporter
expression was speciﬁc for EHV-1 genes. In a similar reporter assay,
luciferase activity was measured from reporter plasmids that used
the simian vacuolating virus 40 (SV40) large T antigen promoter
and the human cytomegalovirus (CMV) IE promoter. In the
presence of UL4P, luciferase activity was decreased 90% from
these heterologous viral promoters as well (Fig. 6A), indicating
that UL4P inhibition is not virus speciﬁc. The inhibitory effect of the
UL4P was not speciﬁc for the ﬁreﬂy luciferase reporter gene as
similar levels of inhibition were obtained in assays that employedrescence with puriﬁed anti-UL4P antibody. RK13 cells were transfected with either the
EHV-1. Cells were ﬁxed with 4% paraformaldehyde at 48 hours post-transfection or at
iﬁed anti-UL4P antibody was used as the primary antibody and an Alexa Fluor 488 goat
n. Coverslips were mountedwith a DAPI solution to stain nuclei (top photograph of each
lower panels.
Fig. 5. Luciferase assays examining the effect of the UL4 protein on luciferase expression driven by EHV-1 promoters of all gene classes. RK13 cells in 24-well plates were transfected
with 0.5 pmol of the expression plasmids pCMV–UL4, pSV–IE, or both plasmids, along with 1 pmol of the luciferase reporter plasmid under the control of the EHV-1 (A) immediate
early promoter; or early promoters (B) EICP0, (C) thymidine kinase (TK), and (D) IR2, or late promoters (E) ETIF and (F) glycoprotein K (gK). Luciferase activity was assayed at 48 hours
post-transfection as described in Materials and methods.
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of cellular promoters was tested to ascertain whether expression of
the UL4 protein affects non-viral gene expression. To this end,
expression of the UL4 protein was found to inhibit luciferase
activity driven by the GAPDH, eIF4E, IFNβ, and HPRT cellular
promoters by 44%, 86%, 75%, and 78%, respectively (Fig. 6B). These
decreases in luciferase activity were not attributable to cytotoxicity
in the presence of the UL4 protein, as demonstrated by similar
levels of cell viability in cells expressing the UL4P compared to non-
transfected cells (data not shown). Taken together, the data
presented in Figs. 5 and 6 indicate that the UL4 protein negatively
affects gene expression, not only from viral promoters but cellular
promoters as well.
UL4 is not required for EHV-1 lytic replication
After observing the inhibitory activity of the UL4 protein against a
broad range of viral and cellular promoters, we wanted to examine if
UL4 plays an essential role in EHV-1 lytic infection. Itwas hypothesizedthat deletion of the UL4 gene would increase the ability of the virus
to replicate due to the absence of the additional inhibitory activity
of the UL4P. To begin to address this hypothesis, a UL4-null EHV-1
was generated utilizing the galK bacterial artiﬁcial chromosome
(BAC) technology (Rudolph et al., 2002; Warming et al., 2005).
Initially, the UL4 gene was replaced by the galK gene to create a
UL4-deleted virus. The galK gene was then replaced with a mutant
form of UL4 that contained a STOP codon at position 18 within the
amino acid sequence (UL4aa18stop) or a wild-type UL4 to generate
a revertant virus (ΔUL4R). Once the mutant and revertant BACs
were generated, the gross genomic structure was examined by
BamH I restriction enzyme digestion. Fig. 7A demonstrates that the
process used for generating the mutant and revertant BACs did not
result in any spurious recombination events or alterations in the
overall genomic structure, as evidenced by similar digestion
patterns of the parental RacL11, ΔUL4R, and UL4aa18stop BACs.
The second BamH I fragment in the ΔUL4 (galK+) BAC migrated in
agarose gels more slowly than the other BACs, indicative of the
additional base pairs within the galK gene compared to the UL4
Fig. 6. Luciferase assays examining the effect of the UL4 protein on luciferase expression
driven by heterologous viral promoters or cellular promoters. (A). Luciferase activity
driven by the SV40 large T antigen promoter or the CMV IE promoter as compared
to activity controlled by the EHV-1 IE promoter. (B). Luciferase activity driven by
cellular promoters glyceraldehyde phosphate dehydrogenase (GAPDH), eukaryotic
initiation factor 4E (eIF4E), interferon β (IFNβ), or hypoxanthine–guanine
phosphoribosyltransferase (HPRT).
Fig. 7. Generation and veriﬁcation of the UL4aa18stop EHV-1 and ΔUL4R revertant
EHV-1 by galK BAC technology. Homologous recombination was used to delete the UL4
gene as described in Materials and methods. Brieﬂy, PCR was utilized to append UL4
DNA ﬂanking sequences to the galK gene. SW106 E. coli harboring the EHV-1 BAC were
transformed with the resultant PCR product and plated on positive selection plates. To
generate the revertant BAC, wild-type UL4 sequences were transformed into bacteria
containing the mutant BAC and plated on negative selection plates with 2-
deoxygalactose. The mutant and revertant BAC genomes were analyzed and veriﬁed
by (A) BamH I restriction enzyme digestion and (B) Southern blot analysis. (C) RK13
cells were transfected with each of the three BAC genomes to generate wild-type,
UL4aa18stop, and ΔUL4R viruses. RK13 cells were then infected with each virus, and at
9 hours post-infection lysates were prepared and subjected to western blot analysis
with the puriﬁed anti-UL4P antibody.
371R.A. Charvat et al. / Virology 412 (2011) 366–377gene (Fig. 7A; lane 2). Southern blot analysis for the presence of the
UL4 gene within the various BACs revealed that the UL4 sequence
was absent from the ΔUL4 (galK+) BAC, while the UL4-speciﬁc
probe hybridized to DNA sequences within the parent, mutant, and
revertant BACs (Fig. 7B). Furthermore, PCR analysis and DNA
sequencing veriﬁed that the BACs were correct (data not shown).
To determine whether UL4 was essential for EHV-1 replication,
the BACs were transfected into permissive RK13 cells. As shown in
Fig. 8A, each BAC resulted in the formation of plaques in transfected
cells, indicating that UL4 is dispensable for EHV-1 lytic replication.
However, it was observed that the plaques formed by the
UL4aa18stop virus were smaller in size compared to those of the
parent and revertant viruses, being approximately one-third the size
of wild-type and revertant plaques (Fig. 8B). To verify that the stop
mutant virus did not produce UL4 protein, lysates from cells
infected with the wild-type, mutant, and revertant viruses were
subjected to western blot analysis. As expected, the UL4 protein was
detected in cells infected with the wild-type RacL11 and ΔUL4R
viruses, but not in cells infected with the UL4aa18stop virus
(Fig. 7C). These data indicated that the UL4 protein is not essential
for EHV-1 replication, but the smaller plaque size of the UL4aa18-
stop virus may indicate a deﬁciency in its ability to replicate or
spread efﬁciently.
Single-step growth kinetics experiments performed to address
this possibility revealed that the UL4aa18stop mutant replicated
with similar kinetics and to equivalent levels as the wild-type and
revertant viruses that express UL4 (Fig. 9A). Similar virus titers were
obtained from the extracellular supernatant of RK13 cells infected
with all three viruses, indicating that impairment of virion release is
not responsible for the smaller plaque phenotype. Finally, celltropism was examined to determine whether UL4P plays a role in
expanding the host range of EHV-1, as shown for the EHV-1 early
IR4 regulatory gene (Breitenbach et al., 2009) as well as for the IR4
homologue EICP22 of HSV-1 (Poffenberger et al., 1993; Post and
Roizman, 1981). The UL4aa18stop virus was able to replicate in cells
of mouse, rabbit, equine, monkey, and human origin (Fig. 9B). Virus
titers in cells infected with all three viruses were similar, with
exceptions of mouse L-M and human HeLa cells, for which an
approximately one log reduction in maximal virus titer was
observed for the UL4aa18stop mutant virus, indicating that UL4
does not contribute to the broad host range of EHV-1 (O'Callaghan
and Osterrieder, 2008). However, upon detailed statistical analysis
of the viral titers from multiple experiments, we found that the
values were signiﬁcantly different between wild-type and the
UL4aa18stop EHV-1 for all cell types. Although the levels of
maximal virus production were statistically different, the biological
relevance is not likely to be consequential.
The UL4 gene is not a virulence factor in the CBA mouse model of
EHV-1 pathogenesis
Although no striking differences were observed between the
UL4-mutant virus and the parental EHV-1 in their abilities to infect
and replicate in cell culture, we wanted to determine whether the
UL4 gene plays a role in EHV-1 pathogenesis. Utilizing the well
characterized CBA mouse model of EHV-1 infection (Colle et al.,
1996; Frampton et al., 2002, 2004; Matsumura et al., 1996;
O'Callaghan and Osterrieder, 2008; Smith et al., 2000, 2005), groups
of 12 female mice were intranasally inoculated with wild-type,
UL4aa18stop, or ΔUL4R viruses as well as with sterile medium for
Fig. 8.Morphology of plaques produced on RK13 cells transfected with the parent, UL4aa18stop, and ΔUL4R BACs. (A) RK13 cells were transfected with the various BACs, overlaid
with medium containing 1.5% methylcellulose, and examined after 5 days for plaque formation by staining with 0.5% methylene blue dye. (B) Plaque size was analyzed with the
ImageJ software (Materials and Methods). 30 plaques produced by each virus were measured and the Student's-t test was used for statistical analysis.
Fig. 9. Growth kinetics and cell tropism of the wild-type EHV-1, UL4aa18stop EHV-1 and
ΔUL4R EHV-1. (A) RK13 cells in 60-mm dishes were infected with the wild-type, mutant,
and revertant viruses at an MOI of 5. Virus was harvested from the extracellular
supernatant as well as from freeze–thawed cells at the indicated times post-infection and
enumeratedbyplaqueassay. (B) Theability of thewild-type,mutant, and revertant viruses
to replicate in various cell types was determined by infecting mouse L–M, rabbit RK13,
equine NBL-6, African green monkey Vero, and human HeLa cells at a MOI of 5. Maximal
viral titers at 72 hours post-infection were determined by plaque assay on RK13 cells.
372 R.A. Charvat et al. / Virology 412 (2011) 366–377a control group, and monitored for signs of morbidity and
mortality over the course of 9 days. As expected, mice in the
sterile medium group demonstrated no signs of infection and
exhibited increases in body weight (Fig. 10A). On the other hand,
all mice infected with each of the three EHV-1 displayed rufﬂed
fur and a huddling phenotype, along with signiﬁcant decreases in
overall body weight (Fig. 10A). EHV-1 lacking UL4 gene expression
caused decreases in body weight similar to that of the wild-type
highly pathogenic EHV-1, suggesting that UL4 is not required for
EHV-1 pathogenesis in the mouse. Furthermore, mortality rates
were similar for mice infected with either the wild-type virus or
the UL4aa18stop EHV-1 (Fig. 10B). In cell culture, there was an
approximate one log decrease in the ability of the UL4aa18stop
mutant virus to replicate in mouse L–M cells compared to the
parental virus (Fig. 9B). To determine whether the reduced ability
of the UL4-mutant virus to replicate in mouse cells in culture was
likewise reﬂected in vivo, infected mice were sacriﬁced at days
2, 3, and 4 post-infection, and virus was titered from infected
lungs. As shown in Fig. 10C, the UL4aa18stop virus replicated as
efﬁciently as the wild-type EHV-1 in murine lungs. Taken together,
the results from these animal experiments indicate that the UL4
gene is not a determinant of virulence for EHV-1.
Viral transcripts of all gene classes are increased in the absence of UL4
protein synthesis
We previously observed that the UL4P was capable of inhibiting
luciferase gene expression driven by representative EHV-1 promoters
from all three gene classes (Fig. 5). To extend these ﬁndings, the effect
of UL4P on the synthesis of EHV-1 transcripts was addressed. Cells
were infected with wild-type virus or the UL4aa18stop EHV-1 and
examined for the effect of the absence of the UL4 protein synthesis on
the level of selected IE, E, and L transcripts. RNA was isolated and
analyzed by northern blot assays at 4 hpi for IE, 8 hpi for early TK, and
12 hpi for late gK gene expression. As shown in Fig. 11, the levels of
Fig. 10. Comparison of the pathogenic properties of wild-type, UL4-mutant and revertant
EHV-1 in the CBA mouse model. Groups (n=12 mice) of 6 week old female CBA mice
were mock infected with sterile medium or were infected intranasally with 1.25×106pfu
of wild-type RacL11, UL4aa18stop, or ΔUL4R EHV-1. Mice were monitored daily for
clinical signs of infection, gain or loss in body weight, and morbidity. (A) Changes in body
weight; (B) Percent survival; and (C) Virus lung titer. Whole lungs were harvested from
mice sacriﬁced on days 2, 3 and 4 post-infection, and virus was titered by plaque assay.
Fig. 11. Northern blot analysis examining gene expression in cells infected with wild-
type (WT) or STOP-mutant EHV-1. RK13 cells were infected with wild-type EHV-1 or
the UL4aa18stop EHV-1, and RNA was isolated at 4, 8, and 12 hours post-infection.
Northern blot analysis was used to determine transcript levels for the immediate early
(IE) gene, the early thymidine kinase (TK) gene, and the late glycoprotein K (gK) gene.
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absence of the UL4 protein as compared to those of WT infected cells.
Densitometry measurements revealed that the levels of the IE, TK, and
gK transcripts were increased a minimum of 20% in the absence of the
UL4P, and in repeated experiments these increases were as great as
42%. These data indicate that the absence of the UL4P allows for
increased viral transcription at all times during infection, and that the
UL4P is indeed an inhibitor of EHV-1 gene expression.
Discussion
The EHV-1 UL4 gene, conserved within the genome of defective
interfering particles, has no attributed function during lytic
replication or DIP-mediated persistent infection (Baumann et al.,
1984, 1986; Ebner et al., 2008; Ebner and O'Callaghan, 2006). In this
report, we presented ﬁndings suggesting that this early gene
encodes an inhibitory protein that negatively affects viral and
cellular gene expression. The expression of the UL4 protein was
capable of inhibiting gene expression driven by promoters from all
EHV-1 gene classes by greater than 75%. These data appear very
similar to the results from experiments concerning the IR2 protein, a
negative regulatory protein that was demonstrated to down-
regulate all EHV-1 gene promoters tested to date (Kim et al.,
2006). Comparing the broad negative regulatory activity of the IR2P
and UL4P suggests that UL4P may serve as an auxiliary inhibitory
protein to govern EHV-1 gene expression during lytic infection.
However, this inhibitory function appears to differ from that
reported for the HSV-1 UL55 protein (Block et al., 1991), which
shares only 32% amino acid identity with UL4P. In that report, the
authors concluded that the inhibition of transient gene expression
relied on the presence of other alpha genes expressed in conjunction
with the UL55 protein, such that the UL55 protein alone was not
sufﬁcient to negatively affect viral gene expression. Conversely, in the
case of the UL4 protein, EHV-1 gene expression was signiﬁcantly
inhibited when only the UL4P was expressed. Although these homologs
may have an inhibitory function in common, our ﬁndings suggest that
their mechanism of action is different. However, we cannot rule out the
possibility that in the prior study involving HSV-1 UL55, alpha genes
were required solely for the efﬁcient expression of the UL55 gene. In
that case, the alpha genes per se contributed no inhibitory function, and
thus it is conceivable that UL4 and UL55 proteins function through a
similar mechanism. We are interested in exploring how the UL4
protein functions to inhibit gene expression, and current work is
focused on elucidating a mechanism. Due to the broad inhibitory
activity of the UL4P, it appears that the mechanism is not gene-
speciﬁc as supported by the fact that the UL4P does not bind to
speciﬁc promoter DNA sequences (data not shown). We have
considered the possibility that the UL4 protein interacts with
another protein involved in gene expression. GST-pulldown assays
are being utilized to examine protein-protein interactions that may
occur between UL4P and other viral and/or cellular proteins. In
preliminary studies, the UL4 protein did not interact with the IEP;
however, it appears that the UL4P functions at the level of gene
transcription via an interaction with general transcription factors
(unpublished data).
To determine whether the inhibitory function of UL4P was
important for viral replication, a mutant virus (UL4aa18stop) was
generated. Surprisingly, we found that the replication kinetics, cell
tropism, and pathogenesis of an EHV-1 lacking UL4 expression were
similar to those of the parental and UL4 revertant viruses (Figs. 9
and 10). These ﬁndings were contrary to our hypothesis that
removing UL4 gene expression would allow enhanced growth of the
mutant virus compared to wild-type EHV-1. As UL4 is not a diploid
gene, serial passage of the UL4aa18stop EHV-1 was not expected to
result in its reversion to a wild-type phenotype. Indeed, the
UL4aa18stop virus failed to produce the UL4 protein upon serial
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(VZV) ORF3 protein is a UL4P counterpart that has 37% identity in
amino acid sequence. Similar to these ﬁndings with the UL4-mutant
EHV-1, it was shown that deletion of VZV ORF3 did not affect virus
replication in vivo or in vitro (Zhang et al., 2007). One signiﬁcant
difference between the UL4aa18stop EHV-1 and the parental virus
was a reduction in plaque size (Fig. 8). One possible explanation for
the smaller plaques is that the virus has a defect in the ability to
egress from infected cells, but that possibility was not supported by
the observation that the extracellular virus titers were identical for
RK13 cells infected with the parental virus and the UL4aa18stop
virus.
During DIP-mediated persistent infection, it is believed that the
highly expressed IR4/UL5 hybrid protein is responsible for mediat-
ing the interference of standard virus replication, as demonstrated
by the observation that recombinant DI particles deleted of the UL3
and UL4 genes and engineered to express only the hybrid protein
retained DIP interference activity (Ebner et al., 2008). However, it
remains unclear what actually triggers the establishment of
persistent infection and how high levels of DIP maintain persistent
infection. Here, we presented data that demonstrate that the UL4
protein negatively affects all EHV-1 gene classes. As this gene is
conserved perfectly within the DIP genome and expressed at very
high levels in persistently infected cells (Gray et al., 1989), it is
possible the UL4 protein could greatly impair the expression of
standard viral genes. This possibility is supported, in part, by the
ﬁnding that EHV-1 gene expression is tempered in cells infected
with the wild-type virus that expresses UL4P, as compared to gene
expression in cells infected with the UL4aa18stop mutant EHV-1. This
broad inhibitory activity may facilitate the establishment and/or
maintenance of DIP-mediated persistent infection. As attractive as this
may be, the studies to determine the role UL4 plays during persistency
will require a better understanding of the function(s)mediated by this
early gene product.
These studies are the ﬁrst to characterize UL4 as a member of
the early class within the EHV-1 gene program. The UL4 protein
localizes within both the nucleus and cytoplasm of infected cells,
but is not a component of mature virus particles. The luciferase
reporter assays demonstrated that the UL4P is an inhibitory protein,
a ﬁnding that was supported by the results of the viral gene
expression studies using the UL4aa18stop EHV-1. Thus, the UL4
protein joins the IR2P as the second EHV-1 early gene product that
possess predominantly negative activity. Current studies are
addressing how this protein mediates this inhibitory outcome in
the case of EHV-1 genes and if this mechanism applies to genes of
heterologous viruses and host cells.
Materials and methods
Cell culture and virus propagation
Mouse L-M, rabbit RK13, equine NBL-6, African green monkey
Vero and human HeLa cells were grown in Dulbecco's minimum
essential medium (DMEM) supplemented with either 5% or 10% fetal
bovine serum at 37°C in a 5% CO2 incubator. The pathogenic EHV-1
strain RacL11 was propagated in equine NBL-6 cells, while the
attenuated KyA strain was grown in mouse L–M cells. After growing a
high-titer stock of KyA virus, the supernatant virus was collected and
clariﬁed by removing cells by centrifugation. Highly puriﬁed virions
were prepared as previously described in detail (O'Callaghan and
Randall, 1976; Perdue et al., 1974).
Plasmids
Manipulation and cloning of the expression plasmids were
performed according to the procedures described by Sambrook et al.(1989). pGEX-UL4, which expresses the UL4 gene as a GST fusion
protein, was generated by PCR amplifying the UL4 gene from the
RacL11 BAC (Rudolph et al., 2002) to include the restriction enzyme
sites EcoR I and Sal I with forward primer: 5′-CATGAATTCC-
CATGCTGCCGGCAAACCGCGCAGAACAC-3′ and reverse primer: 5′-
CTAGGTCGACTTATCGTTTATTTTCTCGCTGGCGCTCTTTGGCCGA-3′. The
PCR product and the pGEX-4T-2 plasmid were digested with the
appropriate enzymes and ligated. pGFP-UL4 expresses a GFP–UL4
fusion protein and was generated by PCR using forward primer: 5′-
CATGTGTACAAGATGCTGCCGGCAAACCGCGCAGAA-3′ and reverse
primer: 5′-CATTGCGGCCGCTTATCGTTTATTTTCTCGCTG-3′ to append
restriction enzyme sites BsrG I and Not I, respectively, to the UL4 gene.
The digested insert was cloned into the pEGFP–N1 plasmid that
contains the enhanced GFP gene under the control of the HCMV IE
promoter. The pUL4–GFP plasmid expresses an amino-terminal
UL4–GFPfusionprotein.PCRwasusedtoattachEcoRIandBamHIenzyme
sites to the UL4 gene using forward primer: 5′-AATTGAATTCCGCCAC-
CATGCTGCCGGCAAACCGCGCAGAAC-3′ and reverse primer: 5′-CATGG-
GATCCCGTTTATTTTCTCGCTGGCGCTCTTTG-3′, respectively. The
digested fragment was again inserted into the pEGFP–N1 plasmid.
To generate pCMV–UL4, an expression plasmid that expresses the
UL4 gene under the control of the HCMV IE promoter, forward
primer: 5′-AATTGAATTCCGCCACCATGCTGCCGGCAAACCGCGCA-
GAAC-3′ and reverse primer: 5′-CATTGCGGCCGCTTATCGTT-
TATTTTCTCGCTG-3′ were used to add the EcoR I and Not I sites to
the UL4 gene, respectively. The digested insert was then cloned into
.1pt?>the pEGFP–N1 plasmid to replace the GFP gene. pUL4–Luc, a
reporter plasmid that contains the ﬁreﬂy luciferase gene driven by
the UL4 promoter, was created using PCR to attach Kpn I and Bgl II
restriction sites ﬂanking the UL4 promoter region. Forward primer:
5′-CATGGTACCCCAACGCAAACAGTTGGCACCGTG-3′ and reverse
primer: 5′-CATAGATCTCAGGCTGGGAATTTGCTCGACTGAAG-3′ were
used. The resulting 1.5 kb enzyme fragment encompassing the UL4
promoter with TATA box was inserted into the pGL3–Basic plasmid.
The remaining expression and reporter plasmids were generated
elsewhere (Bowles et al., 2000; Holden et al., 1995; Kim and
O'Callaghan, 2001; Smith et al., 1992; Zhao et al., 1995).Expression and puriﬁcation of GST–UL4 fusion protein
The induction of GST fusion protein synthesis and its puriﬁcation
have been described previously (Albrecht et al., 2004; Jang et al., 2001).
To prepare a puriﬁed UL4 protein lacking the GSTmoiety, GST–UL4was
treated with a thrombin cleavage capture kit (Novagen, Madison, WI)
per the manufacturer's instructions, and the GST portion was
removed using GST-bind resin beads (Novagen). The puriﬁed protein
was concentrated using Amicon Ultra centrifugation ﬁlter devices
with a size exclusion of 10 and 30 kDa (Millipore, Billerica, MA).Generation of anti-UL4 protein polyclonal antibody
Antibody generation has been described elsewhere (Albrecht et al.,
2004). Brieﬂy, two New Zealand White rabbits (approximately 4 kg
per rabbit) were immunized with either the GST–UL4 fusion protein
(OC94) or the puriﬁed UL4 protein (OC95). The primary inoculumwas
emulsiﬁed in Freund's complete adjuvant, and after 4–8 weeks,
booster immunizations emulsiﬁed in incomplete Freund's adjuvant
were administered every 14 days for a total of ﬁve booster injections
for each rabbit. Before each booster injection, small quantities of
serum were drawn from each rabbit to test antibody titers before the
ﬁnal bleed was performed. The anti-UL4P antibody was puriﬁed using
protein A agarose beads (Pierce, Rockford, IL) according to the
manufacturer's directions. The working dilution in western blot
assays was 1:5000 or greater.
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RK13 cells were seeded onto No. 1.5 glass coverslips (Fischer
Scientiﬁc, Pittsburgh, PA) in the bottom of a 6-well plate. The cells
were either infected with wild-type RacL11 EHV-1 or transfected
with the expression plasmids pCMV–UL4 or pUL4–GFP. Infected
cells were ﬁxed at 12 hours post-infection, while transfected cells
were ﬁxed at 48 hours post-transfection. Cells were ﬁxed with a 4%
paraformaldehyde solution in PBS, and cellular membranes were
permeabilized with 0.2% Triton X100 in PBS. After washing the cells
with PBS, 10% goat serum in PBS was used to block non-speciﬁc
antibody interactions. Anti-UL4P OC95 antiserum was used as the
primary antibody at a dilution of 1:100 in PBS/0.1% Tween-20 and
the secondary antibody was Alexa Fluor 488 goat anti-rabbit IgG
(Invitrogen, Carlsbad, CA) at 1:100 in PBS/0.1% Tween-20. Unbound
antibody was removed by washing, and the coverslips were
removed from the 6-well plates and placed on glass slides. SlowFade
Gold antifade reagent with DAPI (Invitrogen) was used as the
mounting solution (arrows indicate nuclei in Fig. 4). Clear nail polish
sealed the edges of the coverslips, and the slides were viewed on a
Nikon Eclipse TE300 inverted ﬂuorescent microscope (Melville, NY).
Cells were separated into cytoplasmic and nuclear fractions by the
following procedure, modiﬁed from Muramatsu et al. (1963). Cells
were washed with cold PBS, then scraped and pelletted in a
microfuge tube. Resuspend pellets in ice-cold Buffer A (10 mM
HEPES, pH 7.9; 1.5 mMMgCl2; 10 mMKCl; 0.5 mMDTT) and keep on
ice for 5 min. Cells were disrupted by repeated passage through a 26
gage needle. Disrupted cells were centrifuged at 300 g for 5 min at
4 °C to pellet the nuclei. The supernatant was saved as the
cytoplasmic fraction. The nuclear pellet was resuspended in sucrose
buffer A (0.25 M sucrose, 10 mM MgCl2), layered over a cushion of
sucrose buffer B (0.88 M sucrose, 0.5 mMMgCl2), and centrifuged at
3000 g for 10 min at 4 °C. Nuclear pellets were disrupted with RIPA
buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 1% NP-40; 0.5%
deoxycholate) and centrifuged at 3000 g for 10 min at 4 °C to pellet
insoluble debris.
Luciferase reporter assays
RK13 cells were seeded into 24-well plates and used the
subsequent day at a conﬂuency of 80%. Cells were transfected
using lipofectin (Invitrogen) and Opti-MEM medium (Gibco, BRL,
Carlsbad, CA) as detailed elsewhere (Ahn et al., 2007). Brieﬂy, 1 pmol
of the various reporter plasmids and 0.5 pmol of the expression
plasmids were co-transfected into RK13 cells. Eight hours later,
regular growth medium was added, and luciferase activity was
assayed at 48–72 hours post-transfection utilizing a luciferase assay
kit (Promega, Madison, WI) and a POLARstar OPTIMA plate reader
(BMG LABTECH Inc., Cary, NC) following the manufacturer's
instructions.
Generation and conﬁrmation of UL4-null EHV-1
A RacL11 BAC deleted for the UL4 genewas generated through galK
BAC recombineering (Ahn et al., 2010; Warming et al., 2005). To
replace the UL4 gene, PCR ampliﬁcation (forward primer: 5′-
TTATCGTTTATTTTCTCGCTGGCGCTCTTTGGCCGAGGTTATTCCCC-
TAGCCTGTTGACAATTAATCATCGGCA-3′ and reverse primer: 5′-
ATGCTGCCGGCAAACCGCGCAGAACACTCATCTGATGCAGAGCCGCGG-
GATCAGCACTGTCCTGCTCCTT-3′) was used to append UL4 ﬂanking
sequences to the ends of the galK selection gene, and the subsequent
PCR product was transformed into SW106 E. coli harboring the RacL11
BAC. Bacteria were plated onto positive selection agar plates contain-
ing galactose, and colonies were screened by PCR (5′-CAGACCCA-
GAGCTCCACGCACCGTCC-3′/5′-GCAGATCTTGCTCCCAGACCTGACC-3′
and 5′-CCCTCTTCTCGAACACGCCGATGAAAAAGGCG-3′/5′-GGCAGA-TACCTGCAGCCTTGTATCGGCC-3′) for the correct junction sequences.
The galK marker was replaced with a mutant form of the UL4 gene
that contains a STOP codon at position 18 (underlined; UL4aa18-
stop) or a wild-type form of the UL4 gene to generate a UL4
revertant BAC (ΔUL4R). PCR was used to create the desired DNA
fragments that were transformed into the E. coli harboring the





GAGCCGCGGGA-3′). Transformed bacteria were plated on negative
selection plates containing glycerol and 2-deoxygalactose. Result-
ing colonies were again screened by PCR for the junction
sequences as well as DNA sequence analysis. The desired BACs
were further veriﬁed by BamH I digestion and Southern blot
analysis. To reconstitute the mutant and revertant RacL11 BACs as
standard virus, the BAC sequences were replaced with viral DNA
sequences for the EUs4 gene by transfecting RK13 cells with both
BAC and a plasmid containing the EUs4 sequences. Plaques lacking
GFP expression were plaque puriﬁed for three rounds and then
propagated to high titer on equine NBL-6 cells.
Southern, northern and western blot analyses
Mutant and revertant RacL11 BACs were subjected to BamH I
digestion and then electrophoretically separated on a 0.6% agarose
gel. Digested DNA was transferred onto a positively-charged nylon
membrane (Ambion, Austin, TX) using a semi-dry electroblotter
(Bio-Rad Laboratories, Hercules, CA). The transferred DNA was
hybridized with a fragment of the UL4 gene (PCR product forward
primer: 5′-GGCCTGGGCAGAGTTGGCTGCCTGCC-3′ and reverse
primer: 5′-GCAGATCTTGCTCCCAGACCTGACC-3′) end-labeled with
[γ-32P]ATP (New England Nuclear Corporation, Boston, MA) by T4
polynucleotide kinase (Promega) in ULTRAhyb ultrasensitive
hybridization buffer (Ambion). Free radio-labeled probe was
washed away with 2× SSC/0.1% SDS followed by 0.1× SSC/0.1% SDS.
A ﬁnal wash with 2× SSC was completed before wrapping the
membrane in plastic and exposing to a phosphor screen and scanning
on the molecular imager FX system (Bio-Rad Laboratories). Northern
blot analysis was performed by isolating total RNA from RK13 cells
infected with RacL11 EHV-1 at the indicated times using the RNA-
Bee RNA isolation reagent (AMS Biotechnology (Europe) Ltd,
Abingdon, U.K.) per the manufacturer's procedure (Chomczynski
and Sacchi, 1987). RNA samples were separated on a 6% denaturing
urea-polyacrylamide gel. The above procedures were followed for
transferring and probing the RNA on the membranes. The probe
used was a short fragment of the UL4 DNA (5′-TTATCGTT-
TATTTTCTCGCTGGCGCTCTTTGGCCGAGGTTATTCCCCTAG-3′). West-
ern blot analyses were performed using protein lysates from
RK13 cells infected with virus or transfected with expression
plasmids. The protein samples were separated on 10% SDS
polyacrylamide gels and transferred to nitrocellulose membranes
using the semi-dry electroblotter. Membranes were blocked with
1-5% dry milk in PBS/0.3% Tween-20 (PBST). Membranes were
rinsed with PBST and incubated with EHV-1 speciﬁc primary
antibodies, as indicated, followed by goat anti-rabbit or anti-mouse
secondary antibody conjugated to alkaline phosphatase (Sigma,
Saint Louis, MO). Protein-antibody complexes were visualized
using the AP color reagent (Bio-Rad Laboratories) following the
manufacturer's instructions.
Use of metabolic inhibitors
The procedure for virus infection with the use of metabolic
inhibitors is described elsewhere (Gray et al., 1987). To detect
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the protein synthesis inhibitor cycloheximide (CHX, 100 μg/mL;
Sigma) for 30 min prior to infection with EHV-1. Cells were infected
with wild-type EHV-1 (MOI of 10) and maintained in the presence of
CHX for 4 h, at which time RNAwas isolated. To distinguish early from
late transcripts, cells were treated with phosphonoacetic acid (PAA,
100 μg/mL; Sigma) for 30 min prior to infection and then for 8 h after
infection when RNA was isolated. The RNA was subjected to northern
blot analysis as detailed above.
Growth kinetics, cell tropism and plaque morphology
Cells were seeded into 60 mm dishes to 80% conﬂuency and
infected at an MOI of 5. Virus was harvested from the cells and
supernatant at the indicated times post-infection and serially diluted
to perform plaque assays on RK13 monolayers. Infected monolayers
were incubated with medium containing 1.5% methylcellulose, and
plaques were enumerated after three days by ﬁxing with 10%
formalin and staining with 0.5% methylene blue (Perdue et al.,
1974). Plaque morphology was examined using the ImageJ software
(NIH, http://rsbweb.nih.gov/ij/).
Animal experiments and statistical analysis
Animal experiments were conducted as published previously
(Osterrieder et al., 1996; von Einem et al., 2004). Groups (n=12) of 6
week-old female CBA mice were intranasally infected with
1.25×106 pfu of wild-type RacL11, UL4aa18stop, or ΔUL4R EHV-1 or
mock-infected with sterile medium. Mice were weighed before
infection and every day post-infection for 9 days to monitor changes
in body weight. Mice were sacriﬁced at days 2, 3, and 4 post-infection,
and whole lungs were harvested.Whole lungs were also isolated from
animals that succumbed to virus infection. Lung tissue was disrupted
using silica beads and BeadBeater (BioSpec Products, Inc., Bartlesville,
OK), and virus was titered as described above. Statistical analysis was
performed using the two-tailed Student's-t test to compare changes in
body weight as well as mortality rates.
Gene expression in cells infected with wild-type and UL4aa18stop EHV-1
RK13 cells were infected with wild-type or UL4aa18stop EHV-1 to
determine whether gene expression differs in the absence of the
UL4P. RNA was isolated at 4, 8, and 12 hpi and examined by northern
blot analysis using probes speciﬁc for the IE, TK and gK genes.
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